Jane Street Group, LLC Otonomy, Inc. Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.25 - $2.24 $7,413 - $66,422	29,653 Added 161.21%	48,047 $14,000
Q2 2022 Aug 16, 2022	BUY	$1.72 - $2.51 $31,637 - $46,168	18,394 New	18,394 $38,000
Q2 2021 Aug 16, 2021	SELL	$2.06 - $2.67 $32,232 - $41,777	-15,647 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$2.49 - $6.23 $38,961 - $97,480	15,647 New	15,647 $40,000
Q4 2020 Feb 17, 2021	SELL	$3.48 - $6.47 $121,646 - $226,165	-34,956 Closed	0 $0
Q3 2020 Nov 17, 2020	BUY	$3.16 - $4.36 $110,460 - $152,408	34,956 New	34,956 $142,000
Q4 2018 Feb 15, 2019	SELL	$1.51 - $2.93 $18,739 - $36,361	-12,410 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.95 $41,238 - $62,650	-15,861 Reduced 56.1%	12,410 $34,000
Q2 2018 Aug 15, 2018	BUY	$3.7 - $4.75 $104,602 - $134,287	28,271 New	28,271 $109,000
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $46,425 - $69,924	-11,463 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$2.8 - $5.55 $32,096 - $63,619	11,463	11,463 $64,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.